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Abstract
Background: In vitro platelet aggregation in feline blood samples is a well-known phenomenon in veterinary
clinical laboratories resulting in high numbers of pseudothrombocytopenia. Several attempts have been made
to prevent or dissolve platelet aggregates in feline blood samples and to increase the reliability of feline platelet
counts. Prostaglandin I2 (PGI2) is the most powerful endogenous inhibitor of platelet aggregation but unstable.
Iloprost is a stable PGI2 analogue. The aims of the present study were (1) to evaluate the anti-aggregatory effect
of Iloprost on feline platelet counts and to determine a useful concentration to inhibit platelet aggregation in
EDTA samples from clinically healthy cats, (2) to investigate the effect of Iloprost on hematological blood parameters,
and (3) to determine stability of Iloprost in K3-EDTA tubes for up to 16 weeks. From 20 clinically healthy cats blood was
drawn from the jugular vein and immediately distributed in a 1.3 ml K3-EDTA tube, and two 1.3 ml K3-EDTA tubes
containing 20 ng and 200 ng Iloprost, respectively. A complete blood cell count was performed on the Sysmex
XT-2000iV and the Mythic 18 on eight consecutive time points after collection. Blood smears were evaluated for
the presence of PLT aggregates.
Results: In the absence of Iloprost, pseudothrombocytopenia was observed in 50 % of the investigated samples
that led to significantly decreased optical PLT counts by a mean of 105 x103/μl, which could be prevented by the
addition of 1 μL (20 ng) Iloprost leading to an increase in PLT counts by a mean of 108 x103/μl.
Conclusion: This is the first study showing an anti-aggregatory effect of the PGI2-analogue Iloprost in feline EDTA
blood. In all clinically healthy cats investigated, pseudothrombocytopenia was prevented by adding Iloprost to
EDTA tubes prior to blood collection. Furthermore, Iloprost was very useful in preventing falsely increased WBC
counts in samples with platelet aggregates analyzed on impedance-based hematological instruments. Iloprost
is preferable to PGI2 or PGE1 due to its stability and easy and safe handling properties. Cytological evaluations
of blood smears as well as other hematological parameters were not influenced to a clinically significant degree
by the presence of Iloprost.
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Background
In vitro platelet aggregation in feline blood samples is a
well-known phenomenon resulting in pseudothrombo-
cytopenia, with reported prevalences of 52 % [1], 62 %
[2], and 71 % [3]. Several attempts have been made to
prevent or dissolve platelet aggregates and decrease
pseudothrombocytopenia in feline blood samples to in-
crease the reliability of feline platelet counts. It has
been shown that a citrate-based anticoagulant contain-
ing the platelet inhibitors theophylline, adenosine, and
dipyridamole reduces feline platelet aggregation in
blood samples more effectively than citrate or ethylene-
diaminetetraacetic acid (EDTA) [3]. Tvedten and Korcal
investigated whether mixing blood with a vortex mixer
could disaggregate platelet aggregates mechanically, but
few of the investigated samples appeared to have all
platelet aggregates dispersed [4]. Consequently vortex
mixing does not seem to be a consistent means of cor-
recting the problem of feline platelet aggregation. Pros-
taglandins are synthesized from arachidonic acid by
cyclooxygenase in the cell membranes of nearly all tis-
sues. Both prostaglandin E1 (PGE1) and prostaglandin
I2 (PGI2) have platelet aggregation inhibitory activities,
and PGE1 has been successfully used to inhibit platelet
aggregates in platelet-rich feline plasma [5]. A combin-
ation of an optical platelet count together with adding
PGE1 to EDTA blood collection tubes is recommended
for platelet counting in feline patients with potential
thrombocytopenia [6]. PGI2 is the most potent platelet
aggregation inhibitor, but it is very unstable at physio-
logical pH values and requires strict handling proce-
dures [5]. Three decades ago, the stable PGI2 analogue
Iloprost was synthesized. Iloprost is used as a thera-
peutic agent in human medicine to treat peripheral
vascular diseases, severe pulmonary hypertension, and
thrombangiitis obliterans [7]. Platelet aggregation and
release reactions stimulated by aggregating agents such
as arachidonic acid, collagen, or epinephrine are essen-
tially abolished by nanomolar concentrations of Ilo-
prost. The anti-aggregatory effect of Iloprost is based
on an increase in cyclic adenosine monophosphate
(cAMP) within the platelet. Platelets have high-affinity
binding sites for PGI2 that can also bind Iloprost in a
reversible, saturable manner. The formation of cAMP
by the enzyme adenylate cyclase is mediated via these
receptors. Increasing levels of cAMP within the platelet
influence several processes involved in platelet activa-
tion, including the regulation of phospholipases and
free cytosolic calcium levels [7]. Because of its chemical
and biological stability, universal potent anti-aggregatory
effect, and availability, Iloprost is more likely than PGI2
and PGE1 to be useful in preventing platelet aggregation
in feline blood samples. The aims of the present study
were (1) to evaluate the anti-aggregatory effect of Iloprost
on feline platelet counts and to determine a useful con-
centration to inhibit platelet aggregation in EDTA samples
from clinically healthy cats, (2) to investigate the effect of
Iloprost on hematological blood parameters, and (3) to de-
termine stability of Iloprost in K3-EDTA tubes.
Methods
Pilot study with different Iloprost concentrations
To test the overall effectiveness of Iloprost to prevent
feline platelet aggregation, six different Iloprost amounts
between 1 μg (50 μL of Ilomedin, Schering) and 20 ng
(1 μL of Ilomedin) were tested in blood samples from
five clinically healthy cats well known to build platelet
aggregates in EDTA blood tubes (TVB 99/2007, 100/
2007, and 101/2007 approved by the veterinary office of
the canton Zurich). Just before blood collection, a 1 mL
ampulla containing 20 μg of Iloprost (Ilomedin) was
opened and a predetermined volume was pipetted into
1.3 mL K3-EDTA tubes (Sarstedt) with a micropipette
(Calibra digital, Socorex Isba S.A.). Blood was collected
with a needle (22 G, Neolus Terumo) and a 5 mL syr-
inge (Omnifix, B. Braun) from the jugular vein. The
needle was immediately removed after collection, and
equal amounts of blood were placed in a K3-EDTA tube
and three K3-EDTA tubes containing different Iloprost
concentrations. The two persons involved in the blood
collection process ensured that filling, closing, and mix-
ing of all blood tubes occurred nearly simultaneously.
All tubes were gently mixed for 2 min. A second blood
collection was performed to test the remaining three
Iloprost concentrations. For three of the five cats, blood
collection was performed under deep sedation (10 mg/kg
ketamine, Narketan, Vétoquinol AG in combination with
0.1 mg/kg midazolam, Dormicum, Roche Pharma AG).
The blood samples were analyzed at 15 min (min),
30 min, and 1, 2, 3, and 4 h (h) after blood collection.
Between time points, the blood was mixed at room
temperature on an automated mixer (Rock ‘n Roller
34201, Snijders Scientific B.V., AR). At each time point,
blood samples were analyzed on the Sysmex XT-
2000iV (Sysmex Corporation) for impedance and op-
tical platelet counts and for total white blood cell
(WBC) counts [8], and a blood smear was prepared and
stained (HemaTek, Siemens).
Approval for collecting blood samples was given by
the veterinary office of the canton Zurich, Switzerland
(TVB number 99/2007, 100/2007, and 101/2007).
Evaluation of the effect of 20 ng (1 μL) and 200 ng
(10 μL) of Iloprost on 20 feline EDTA samples
Blood samples were next obtained from the jugular vein
of 20 clinically healthy cats (TVB 99/2007, 100/2007,
and 101/2007). Blood collection was performed as de-
scribed for the pilot study. Immediately after collection,
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the needle was removed and equal amounts of blood
were placed in 1.3 mL K3-EDTA tubes without Iloprost,
with 1 μL (20 ng) Iloprost, and with 10 μL (200 ng) Ilo-
prost, respectively. Blood collection was performed
under deep sedation in 10 of the 20 cats. The blood
samples were analyzed at 15 min and 1, 2, 3, 4, 6, 8, and
24 h after blood collection. Between time points, the
blood was mixed on an automated mixer at room
temperature (Rock ‘n Roller 34201, Snijders Scientific
B.V). At each time point, the blood samples were ana-
lyzed on the Sysmex XT-2000iV (Sysmex Corporation)
for a complete blood cell count including impedance
and optical platelet counts, and a blood smear was pre-
pared. Seven cats with platelet aggregates were addition-
ally analyzed on the Mythic 18 instrument (Orphée SA)
for total WBC counts at two time points [9]. The first
measurement was immediately after blood collection,
and the second was performed when platelet counts on
the Sysmex XT-2000iV dropped under the lower refer-
ence limit (180 × 103/μL) for the first time. All blood
smears were assessed by one of the authors for the pres-
ence of platelet aggregates by applying the following
scoring system per slide: 0, no aggregates; 1, aggregates
of 2–5 platelets; 2, aggregates of 6–15 platelets; 3, aggre-
gates of 16–50 platelets; and 4, aggregates of >50 plate-
lets. Furthermore, blood smears were evaluated for
estimation of WBC counts and to determine whether
Iloprost has an effect of WBC and RBC morphology.
Iloprost stability study
Iloprost stability was investigated over 16 weeks using
blood samples from two clinically healthy cats known
to develop platelet aggregates after each blood collec-
tion. Both cats had previously been used in the second
experiment of the present study. Before study onset, 40
EDTA tubes (Sarstedt, 1.3 mL) were prepared with
1 μL (20 ng) of Ilomedin. Twenty tubes were stored at
room temperature, and another 20 tubes were stored at
37 °C in an incubator. Blood collection was performed
after 1, 2, 3, 6, 8, 12, and 16 weeks of storage. At each
time point, 3 mL of blood was collected from the jugu-
lar vein as previously described and distributed equally
into one K3-EDTA tube, one K3-EDTA tube with 1 μL
(20 ng) Iloprost stored at room temperature, and one
K3-EDTA tube with 1 μL (20 ng) Iloprost stored at 37 °C.
The blood samples were analyzed 1, 2, 3, and 4 h after
collection in the Sysmex XT-2000iV for optical platelet
counts.
Statistical analysis
Statistical analysis was performed with the software
packages R and nlme [10]. Linear mixed effects models
were used to model the outcome variable platelet
counts, WBC, red blood cell (RBC), hematocrit (HCT),
hemoglobin concentration (HGB), mean corpuscular
hemoglobin (MCH), mean corpuscular volume (MCV),
and mean corpuscular hemoglobin concentration (MCHC)
measured on the Sysmex XT-2000iV, with the potential
explanatory variables time, Iloprost administration (yes
or no), aggregates (no: scoring index blood smear
evaluation 0, 1; or yes: 2, 3, 4), an interaction term be-
tween Iloprost and aggregates as fixed effects, and cats
as random effects to account for potential within-
animal clustering. Model selection and validation were
based on Akaike’s Information Criterion and the resid-
uals for normality and homogeneity were checked visu-
ally. The results of the linear mixed effects models are
given as effect sizes and their corresponding standard
errors and p-values. To evaluate the changes in WBC
counts analyzed with the Mythic 18 instrument (Orphée
SA) at two time points, paired t-tests with and without
Iloprost administration were performed.
Bar charts were made using GraphPad Prism (version
3.00 for Windows, GraphPad Software).
Results
Pilot study with different Iloprost concentrations
Within 4 h, mean platelet counts decreased in all
EDTA tubes without Iloprost at timepoints 1 h, 2 h,
3 h and 4 h under the lower reference limit (180 × 103/
μL). In the EDTA tubes with Iloprost, mean platelet
counts remained within the reference limits at each of
the six tested Iloprost concentrations (Fig. 1). All
tested Iloprost concentrations were effective to pre-
vent pseudothrombocytopenia.
Evaluation of the effect of 1 μL (20 ng) and 10 μL
(200 ng) Iloprost on 20 feline EDTA samples
Fifty percent of the investigated feline EDTA samples
without Iloprost showed pseudothrombocytopenia, with
platelet counts under the lower reference limit at differ-
ent time points. In EDTA tubes with Iloprost, pseudo-
thrombocytopenia was prevented in all cases; however
platelet aggregates were not completely dissolved. Blood
smear evaluation of EDTA samples with Iloprost yielded
platelet aggregation scores ranging from 0 to 2, whereas
blood smears from EDTA samples without Iloprost had
platelet aggregations scores ranging from 0 to 4. Iloprost
had no effect on WBC and RBC morphology.
The raw data of platelet counts measured by optical
and impedance-based methods per time point, in the
absence or presence of platelet aggregates and Iloprost
administration are shown in Tables 1 and 2. The results
of the linear mixed effects approach to assess potential
effects of Iloprost, presence of aggregates, and an inter-
action between Iloprost and presence of aggregates as
well as time on the optical and impedance-based plate-
let counts are shown in Table 3. In both methods, the
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optical and impedance-based platelet counts, the effect
of Iloprost on increasing the platelet counts (by 108 ×
103/μL and 95 × 103/μL) is mainly seen if aggregates are
present, thus outweighing the effect of aggregates in de-
creasing platelet counts (−105 × 103/μL and −94 × 103/
μL, respectively). This indicates an interaction effect
between Iloprost administration and presence of aggre-
gates, thus meaning that an effect of Iloprost on the
PLT counts is mainly seen in the presence of aggregates
but not in the absence. The interaction effect between
Iloprost and presence of aggregates for each method is
shown in Fig. 2 and Fig. 3. Over time, a slight decrease
in platelet counts was seen. A significant difference be-
tween 1 μL (20 ng) and 10 μL (200 ng) Iloprost could
not be found for either the impedance platelet count or
the optical platelet count in a subsequent analysis using
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Fig. 1 Bar chart showing results from the pilot study with different Iloprost concentrations. Mean optical platelet counts (103/μl) from 5 cats with
platelet aggregation without Iloprost and with 25 ng, 50 ng, 100 ng, 200 ng, 400 ng and 1 μg Iloprost at 0.25 h, 0.5 h, 1 h, 2 h, 3 h and 4 h after
blood collection. The black line indicates the upper reference interval for feline platelets (180 x103/ μL)
Table 1 Means and standard deviations of optical platelet counts per time point, in the absence or presence of aggregates with
and without Iloprost administration
Time
in
hours
Aggregates present Aggregates absent
Ilo yes Ilo no Ilo yes Ilo no
20 ng 200 ng 20 ng 200 ng
mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n
0.15 296 42 4 296 37 4 288 127 5 343 124 16 340 129 16 338 125 15
1 314 41 3 296 53 4 183 138 8 339 119 17 337 126 16 363 125 12
2 285 15 2 275 37 2 81 70 10 342 119 18 337 124 18 365 131 10
3 351 70 3 284 NA2 1 148 105 14 330 123 17 329 119 19 396 161 6
4 276 29 3 304 67 5 179 88 13 334 122 17 331 132 15 369 173 7
6 290 24 3 276 1 2 207 74 12 316 125 17 314 123 18 332 159 8
8 239 NA2 1 330 88 2 205 72 11 287 128 19 286 127 18 309 154 9
24 231 NA2 1 153 NA2 1 182 80 8 230 115 19 230 114 19 274 118 12
1 mean and standard deviation of platelet counts in 103 x μL
2 1 cat
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a linear mixed effects models to compare the effect of
different amounts of Iloprost (Sysmex, P = 0.25; Mythic,
P = 0.83).
No significant effect of Iloprost administration on
WBC, RBC, HGB, HCT or MCV was found. Although
significant (p-values of 0.0012 and 0.004), the effect of
Iloprost administration on MCH and MCHC was con-
sidered to be clinically irrelevant with a decrease of -
0.052 pg (±0.016 pg) and - 0.12 g/dL (±0.04 g/dL). A
significant increase over time for MCV, RBC, HCT,
HGB and MCHC, albeit clinically not relevant, was
observed.
In EDTA samples without Iloprost, mean WBC counts
measured with the Mythic 18 increased strongly at the
second measurement time point compared with the first.
At the first time point mean WBC count was 8.87 × 103/
μL (±2.50 × 103/μL), and at the second time point it was
15.49 × 103/μL (±3.07 × 103/μL 3.07). In contrast mean
WBC counts in EDTA tubes with Iloprost remained
completely stable at 8.66 × 103/μL (±2.24 × 103/μL, ±
2.21 × 103/μL) at both time points. Based on paired t-
tests, the difference between the two time points differed
significantly in the samples without Iloprost (p < 0.0001)
but not in the group with Iloprost administration. Blood
smear evaluation from EDTA samples without Iloprost
showed platelet aggregates in all cats at the second
measurement time point; however no change in WBC
count and distribution was observed compared to the
blood smears from EDTA samples with Iloprost.
Iloprost stability study
Results of the Iloprost stability experiment are displayed
in Table 4. Optical platelet counts in EDTA tubes con-
taining Iloprost at room temperature or in the incubator
were higher than mean platelet counts in EDTA tubes
without Iloprost. Mean platelet counts in EDTA tubes
without Iloprost were below the lower reference limit at
time point 2 h.
Discussion
This is the first study showing a strong anti-aggregatory
effect for the synthetic PGI2 analogue Iloprost on feline
Table 2 Means and standard deviations of impedance-based platelet counts per time point, in the absence or presence of
aggregates with and without Iloprost administration
Time
in hours
Aggregates present Aggregates absent
Iloprost yes Iloprost no Iloprost yes Iloprost no
20 ng 200 ng 20 ng 200 ng
mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n mean1 sd1 n
0.15 266 85 4 278 68 4 276 148 5 310 104 16 300 120 16 295 95 15
1 281 85 3 257 83 4 171 134 8 295 112 17 295 109 16 294 99 12
2 142 81 2 192 22 2 66 57 10 271 111 18 258 113 18 288 113 10
3 282 136 3 154 NA2 1 136 100 14 234 100 17 246 120 19 280 80 6
4 176 45 3 249 119 5 168 83 13 238 118 17 236 111 15 252 112 7
6 175 21 3 186 1.4 2 187 84 12 215 113 17 215 115 18 237 108 8
8 150 NA2 1 303 165 2 181 90 11 191 97 19 188 90 18 237 81 9
24 140 NA2 1 83 NA2 1 152 79 8 137 61 19 141 70 19 202 78 12
1 mean and standard deviation of platelet counts in 103 x μL
2 1 cat
Table 3 Statistical analysis of optical platelet and impedance platelet counts
Value (103/μL) SE (103/μL) P-value
Optical Impedance Optical Impedance Optical Impedance
constant 332.3 287.9 25.5 21.0 <0.0001 <0.001
Ilo −0.4 −25.8 6 7.1 0.9428 0.0003
Aggregates −105.4 −94.4 8.1 9.6 <0.0001 <0.001
Time −3.7 −4.9 0.3 0.3 <0.0001 <0.001
Interaction Ilo:Aggregates 108 95.3 11.3 13.5 <0.0001 <0.001
This table presents the results of a linear mixed effects model with PLT counts as outcome variable. The following variables were included as explanatory variables
in the final model: administration of Iloprost (“Ilo”), presence or absence of aggregates (“Aggregates”), measurements taken over time (“Time”) as well as an
interaction effect between Iloprost and presence of aggregates (“Interaction Test Ilo:Aggregates”). The results are given in the form of the mean effect size
(“Value”) and their corresponding standard error (“SE”) as a measure of uncertainty and the p-values of each explanatory variable. The constant term or intercept
indicates the value at which the fitted regression line crosses the y-axis or in other words corresponds to the mean PLT count if there would be no Iloprost admin-
istration, and no aggregates present at time point 0
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platelet counts. In clinically healthy cats, pseudothrombo-
cytopenia was completely prevented in all blood samples
in EDTA tubes containing Iloprost. Without Iloprost, if
significant numbers of platelet aggregates were present
(score of > 1) in an EDTA blood sample, the mean optical
platelet count decreased by 105 × 103/μL. This decrease
was completely counterbalanced by the presence of Ilo-
prost in the EDTA tube. Iloprost did not affect optical
platelet counts in samples without aggregates or with
score 1 aggregates. For impedance platelet counts, the ef-
fect of Iloprost on aggregates was similar.
Iloprost effectively prevented pseudothrombocytopenia
in the present study, but it did not dissolve platelet ag-
gregates completely. Cats with optical platelet counts
that remained within the reference intervals during the
evaluation period nevertheless showed occasionally small
Fig. 2 Interaction plot for optical platelet (platelet) counts in cats with (Yes) and without (No) platelet (platelet) aggregates. The black dashed line
corresponds to Iloprost (Yes)
Fig. 3 Interaction plot for impedance platelet (platelet) counts in cats with (Yes) and without (No) platelet (platelet) aggregates. The black dashed
line corresponds to Iloprost (Yes)
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platelet aggregates in blood smears, which were classi-
fied according to the scoring index as 1 or 2. In blood
smears from EDTA samples with Iloprost, these platelets
were observed to retain their granules over the evalu-
ation period, and appeared morphologically round. In
contrast, platelets that formed aggregates in samples
without Iloprost lost their shape, formed pseudopods,
and lost their granules. The scoring index used in this
study to judge the presence of platelet aggregates in the
blood smear was limited in that only the size, but not
the frequency of aggregates, was investigated. If a single
platelet aggregate with a score of 2 (6–15 platelets) was
identified, the sample was categorized as having a platelet
aggregate score of 2. In feline samples with unaffected op-
tical platelet counts, platelet aggregates consisted mainly
of only six to seven platelets. The blood smear evaluation
technique used in this study seemed to be a very sensitive
method for detecting platelet aggregates, particularly if the
feathered edges of the smear were examined. From this
observation it can be speculated that a few platelet ag-
gregates consisting only of a small number of platelets
do not influence the optical platelet count of the Sys-
mex XT-2000iV.
Similar to PGI2, PGE1 has platelet anti-aggregatory
properties [5] previously showed that feline platelets
exposed to PGE1 become immediately and persistently
nonreactive to agonists, which prevents platelet aggrega-
tion and consequently improves platelet count accuracy.
Tvedten and Johansson [6] demonstrated higher feline
platelet counts in feline samples containing PGE1, al-
though a complete inhibition of aggregation could not
be achieved. On blood smear evaluation, PGE1-treated
samples had occasional platelet aggregates, but many
more and larger aggregates were seen in EDTA samples.
Although PGE1 has been shown to successfully prevent
in vitro platelet aggregation in blood samples from cats,
it is not used in daily laboratory hematology testing be-
cause of its poor stability.
In vivo, PGI2 is one of the main platelet anti-aggregatory
agents. Similar to PGE1, PGI2 is characterized by poor
stability; it has a half-life of approximately 2 min at 37 °C
and pH of 7.4, and its activity is gone in 20 min at 22 °C
[11]. Use of PGI2 in laboratory hematology testing is not
practical. The synthetic PGI2 analogue Iloprost is both
qualitatively and quantitatively more effective as an inhibi-
tor of platelet aggregation than either PGI2 or PGE1 [7].
Furthermore, Iloprost is available as Ilomedin, an intra-
venous drug in human medicine. Ilomedin is readily
usable due to its pharmacological formulation. In the
present study, all Iloprost concentrations tested showed
the same strong anti-aggregatory effect on feline platelets.
Concentrations for PGI2 causing 50 % inhibition of ADP-
induced platelet aggregation have been reported for differ-
ent species other than the cat, and range from 0.5 to
3.7 ng/mL [11]. Due to the specific peculiarities of the
feline platelet, which appears to be more readily activated
and aggregated compared to other species [12], the
authors assumed that higher amounts of Iloprost would
be needed to inhibit aggregation of feline platelets. To
investigate the effect of Iloprost in a reasonable number
of cat blood samples, 1 μL (20 ng) and 10 μL (200 ng)
of Iloprost were chosen. Both amounts achieved the
same effect, and no significant difference between
EDTA tubes with 1 μL vs. 10 μL was observed. For this
reason, the Iloprost stability study and Iloprost testing
in clinical cases were performed with 1 μL (20 ng)
Iloprost. The smaller amounts are likely sufficient to
prevent pseudothrombocytopenia, but amounts greater
than 1 μL (20 ng) and 10 μL (200 ng) would be needed
to completely prevent platelet aggregation.
The use of Iloprost in veterinary hematology would be
beneficial for preventing pseudothrombocytopenia in fe-
line EDTA samples. Adding Iloprost to EDTA tubes used
for hematological analysis of feline blood samples should
improve the reliability of platelet counts. The main weak-
nesses of PGI2 and PGE1 for routine application are their
poor stability and complex handling procedures. In con-
trast, Iloprost can be stored at room temperature, and is
easy to handle and immediately useable. In the present
study Iloprost was stored for up to 16 weeks in EDTA
tubes at room temperature and at 37 °C. The effective-
ness of Iloprost on platelet aggregates persisted over
the entire storage time. Iloprost did not significantly
affect hematological parameters, cytological evaluation
of the blood smears and the observed decreases in
MCH and MCHC were negligible.
It is a well-known phenomenon in feline blood sam-
ples that platelet aggregates can falsely increase WBC
counts and decrease platelet counts in impedance-based
Table 4 Results of the stability study (measuring time point 2 h)
for cat 1 and cat 2: Platelet counts in the EDTA tube, the EDTA
tube + 20 ng Iloprost stored at room temperature and the EDTA
tube + 20 ng Iloprost stored at 37 °C
Optical platelet
counts (103/μL)
EDTA EDTA + 20 ng
Iloprost stored
at room
temperature
EDTA + 20 ng
Iloprost stored
at 37 °C
cat 1 cat 2 cat 1 cat 2 cat 1 cat 2
Week 1 29 91 292 480 296 461
Week 2 25 22 324 463 280 456
Week 3 11 77 323 528 323 535
Week 6 17 30 358 476 394 477
Week 8 16 21 296 462 313 478
Week 12 33 20 339 448 372 461
Week 16 16 20 288 370 299 395
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hematological instruments [13, 14]. In the present study,
false-positive leucocytosis was observed in six out of
seven EDTA samples, whereas false leucocytosis did not
occur in the EDTA samples with Iloprost. This observa-
tion is important because impedance-based instruments
are widely used in veterinary practices, and false WBC
counts due to platelet aggregation are a common finding.
Using EDTA tubes with Iloprost for hematological analysis
on impedance instruments would improve the reliability
of both WBC counts and platelet counts in cats.
Conclusions
In conclusion, this is the first study showing an anti-
aggregatory effect of the PGI2-analogue Iloprost in feline
EDTA blood. In all clinically healthy cats investigated,
pseudothrombocytopenia was prevented by adding Ilo-
prost to EDTA tubes prior to blood collection. Further-
more, Iloprost was very useful in preventing falsely
increased WBC counts in samples with platelet aggregates
analyzed on impedance-based hematological instruments.
Iloprost is preferable to PGI2 or PGE1 due to its stability
and easy and safe handling properties. Cytological evalua-
tions of blood smears as well as other hematological
parameters were not influenced to a clinically significant
degree by the presence of Iloprost.
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